Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($0.69) per share for the quarter, down from their previous forecast of ($0.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($2.01) EPS and FY2026 earnings at ($1.82) EPS.

Several other research firms have also recently weighed in on ZNTL. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Wedbush restated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday. Finally, Wells Fargo & Company cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.59 on Monday. The business has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.84. The company has a market capitalization of $114.18 million, a price-to-earnings ratio of -0.64 and a beta of 1.75. Zentalis Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $16.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns bought 20,000 shares of the stock in a transaction on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jan Skvarka purchased 60,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the purchase, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in ZNTL. Barclays PLC raised its holdings in Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares in the last quarter. Verition Fund Management LLC increased its position in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares during the period. SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after buying an additional 30,240 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Zentalis Pharmaceuticals by 22.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Finally, Savant Capital LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth $72,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.